|Mr. Vivek Ramaswamy||Founder & Chairman||1.26M||N/A||1985|
|Mr. Matthew Gline||CEO & Director||1.45M||N/A||1984|
|Dr. Eric Venker M.D., Pharm.D.||Pres & COO||981.38k||N/A||1987|
|Dr. Mayukh Sukhatme M.D.||Pres & Chief Investment Officer||910.19k||N/A||1976|
|Mr. Richard Pulik||Chief Financial Officer||N/A||N/A||1979|
|Ms. Rakhi Kumar||Chief Accounting Officer||N/A||N/A||1980|
|Mr. Josh Chen||Gen. Counsel||N/A||N/A||N/A|
|Ms. Kelly Graff||Head of People||N/A||N/A||N/A|
|Ms. Marianne L. Romeo||Head of Global Transactions & Risk Management||N/A||N/A||1968|
|Dr. Woody Sherman Ph.D.||Chief Computational Scientist||N/A||N/A||N/A|
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Roivant Sciences Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.